Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters

Database
Language
Document Type
Year range
1.
BMC Nephrol ; 22(1): 75, 2021 02 27.
Article in English | MEDLINE | ID: covidwho-1105702

ABSTRACT

BACKGROUND: Anti-glomerular basement membrane disease (GBM) disease is a rare autoimmune disease causing rapidly progressive glomerulonephritis and pulmonary haemorrhage. Recently, an association between COVID-19 and anti-glomerular basement membrane (anti-GBM) disease has been proposed. We report on a patient with recurrence of anti-GBM disease after SARS-CoV-2 infection. CASE PRESENTATION: The 31-year-old woman had a past medical history of anti-GBM disease, first diagnosed 11 years ago, and a first relapse 5 years ago. She was admitted with severe dyspnoea, haemoptysis, pulmonary infiltrates and acute on chronic kidney injury. A SARS-CoV-2 PCR was positive with a high cycle threshold. Anti-GBM autoantibodies were undetectable. A kidney biopsy revealed necrotising crescentic glomerulonephritis with linear deposits of IgG, IgM and C3 along the glomerular basement membrane, confirming a recurrence of anti-GBM disease. She was treated with steroids, plasma exchange and two doses of rituximab. Pulmonary disease resolved, but the patient remained dialysis-dependent. We propose that pulmonary involvement of COVID-19 caused exposure of alveolar basement membranes leading to the production of high avidity autoantibodies by long-lived plasma cells, resulting in severe pulmonary renal syndrome. CONCLUSION: Our case supports the assumption of a possible association between COVID-19 and anti-GBM disease.


Subject(s)
Anti-Glomerular Basement Membrane Disease/diagnosis , COVID-19/complications , Anti-Glomerular Basement Membrane Disease/etiology , Anti-Glomerular Basement Membrane Disease/physiopathology , Anti-Glomerular Basement Membrane Disease/therapy , Child , Cyclophosphamide/therapeutic use , Female , Glucocorticoids/therapeutic use , Humans , Immunosuppressive Agents/therapeutic use , Kidney/pathology , Kidney/physiology , Methylprednisolone/therapeutic use , Plasmapheresis , Prednisone/therapeutic use , Recurrence , SARS-CoV-2 , Urinary Bladder/physiopathology , Vesico-Ureteral Reflux/physiopathology
SELECTION OF CITATIONS
SEARCH DETAIL